---

Kurzfassung

• Specific drug delivery via nanoparticles
• Virus like targeting in a two-stage process
• Dose reduction compared to free drug

---

Hintergrund

Poor target cell specificity is currently a major shortcoming of nanoparticles used for biomedical applications. It causes significant material loss to off-target sites and poor availability at the intended delivery site. To overcome this limitation, designed nano-particles that identify cells in a virus-like manner could provide a solution to this problem.

---

Bilder & Videos

---

Lösung

The invention described here involves virus-mimetic nanoparticles that are able to transport drugs into the mesangium of the kidney. The nanoparticles use a novel sequential recognition process that is used in a similar way by viruses to recognize their target cells. In contrast to other nanomaterials, the virus-mimetic particles are able to effectively accumulate in the cells of the mesangium. By encapsulating drug candidates such as pirfenidone or cinaciguat, a rational treatment of diabetic nephropathy can be promised for the first time, which occurs in 40% of the more than 400 million people with diabetes worldwide and for whom there is currently no treatment option other than dialysis and organ transplantation.

---

Anwendungsbereiche

Drug Delivery for Diabetic Nephropathy